-+ 0.00%
-+ 0.00%
-+ 0.00%

AKEBIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF PRALICIGUAT FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

路透·01/06/2026 13:00:06

登錄查看新聞詳情